New & Notable
Understanding pharmaceutical patent thickets, exclusivity
Pharmaceutical companies increasingly rely on dense patent thickets, including continuation patents, to delay competition, extend exclusivity and protect profits.
Novo Nordisk CEO steps down amid increased competition
Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as the company faces heightened competition and a declining share price.
Systemic gaps hinder cell and gene therapy adoption, access
Over 200 cell and gene therapy treatments could be FDA-approved by 2030, but adoption could lag due to structural barriers, limited infrastructure and centralized access.
How digital twins are reshaping clinical trials
As drug development costs soar and timelines tighten, AI digital twins help sponsors cut enrollment, speed timelines and improve trial design, while meeting regulatory standards.
Insights
Insights is research conducted by and for TechTarget Xtelligent Healthcare. Our work aims to leverage Xtelligent’s diverse readership of healthcare professionals across various sectors of the industry to understand real-world challenges and identify effective solutions.
Access All Reports
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
FDA reviews oral GLP-1 semaglutide for obesity
Novo Nordisk is pursuing FDA approval for the first oral GLP-1 semaglutide, aiming to expand Wegovy's indication for chronic obesity and weight management.
-
How GLP-1 drug patents worsen healthcare disparities
Patent extension strategies and high pricing of GLP-1 drugs reinforce patient access barriers, deepening health inequities while generating massive profits and shareholder returns.
-
As the FDA targets synthetic dyes in food, will drugs be next?
The FDA and HHS plan to revoke authorization of two synthetic food dyes and urge the food sector to drop six more by 2026, hinting drug makers could soon face similar pressure.
-
Trump signals shift in drug import tariff policy
Analysts warn Trump's looming threat of pharmaceutical tariffs on drug imports could upend global pharma supply chains, drive up costs and reduce patient access to medicine.
-
FDA clears Dexcom G7 15-Day continuous glucose monitor
Dexcom’s G7 15-Day continuous glucose monitor extends wear, improves usability and accuracy and sets a new bar for diabetes care and integration.
-
Senate Judiciary advances bipartisan drug pricing bills
The Senate Judiciary Committee advanced six bipartisan bills to the full Senate, targeting anti-competitive practices to promote competition and reduce drug prices.
Features
-
Biosimilars set to surge as biologic patents expire
As key biologics near loss of exclusivity in 2030, biosimilars are expected to deliver major savings and drive $120B in market opportunities across the U.S. healthcare system.
-
How Trump's pharma tariffs disrupt drug supply chains
With Trump's tariffs and global retaliation looming, pharmaceutical companies face financial risk, regulatory hurdles and pressure to quickly localize drug supply chains.
-
How Trump’s tariffs threaten MedTech supply chains
President Trump’s proposed 10% import tariffs could disrupt U.S. MedTech supply chains, driving up costs and triggering compliance and manufacturing challenges across the industry.
-
Expanding orphan drug access for rare conditions
Incentives have accelerated orphan drug development, turning rare disease treatments into one of the fastest-growing and most innovative sectors in the biopharmaceutical industry.